These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Whole-cell or acellular pertussis vaccination in infancy determines IgG subclass profiles to DTaP booster vaccination. van der Lee S; Sanders EAM; Berbers GAM; Buisman AM Vaccine; 2018 Jan; 36(2):220-226. PubMed ID: 29199041 [TBL] [Abstract][Full Text] [Related]
5. Effectiveness of a single dose of acellular pertussis vaccine to prevent pertussis in children primed with pertussis whole cell vaccine. De Serres G; Shadmani R; Boulianne N; Duval B; Rochette L; Douville Fradet M; Halperin SA Vaccine; 2001 Apr; 19(20-22):3004-8. PubMed ID: 11282212 [TBL] [Abstract][Full Text] [Related]
6. Reduced risk of pertussis in whole-cell compared to acellular vaccine recipients is not confounded by age or receipt of booster-doses. Sheridan SL; Ware RS; Grimwood K; Lambert SB Vaccine; 2015 Sep; 33(39):5027-30. PubMed ID: 26297874 [TBL] [Abstract][Full Text] [Related]
7. Impact of infant and preschool pertussis vaccinations on memory B-cell responses in children at 4 years of age. Hendrikx LH; de Rond LG; Oztürk K; Veenhoven RH; Sanders EA; Berbers GA; Buisman AM Vaccine; 2011 Aug; 29(34):5725-30. PubMed ID: 21669247 [TBL] [Abstract][Full Text] [Related]
8. Shortcomings of pertussis vaccines: why we need a third generation vaccine. Poolman JT Expert Rev Vaccines; 2014 Oct; 13(10):1159-62. PubMed ID: 25089373 [TBL] [Abstract][Full Text] [Related]
9. Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine compared to recipients of acellular pertussis vaccines in a large US cohort. Witt MA; Arias L; Katz PH; Truong ET; Witt DJ Clin Infect Dis; 2013 May; 56(9):1248-54. PubMed ID: 23487373 [TBL] [Abstract][Full Text] [Related]
10. Different T cell memory in preadolescents after whole-cell or acellular pertussis vaccination. Smits K; Pottier G; Smet J; Dirix V; Vermeulen F; De Schutter I; Carollo M; Locht C; Ausiello CM; Mascart F Vaccine; 2013 Dec; 32(1):111-8. PubMed ID: 24176499 [TBL] [Abstract][Full Text] [Related]
11. Recommendations to control pertussis prioritized relative to economies: A Global Pertussis Initiative update. Forsyth KD; Tan T; von König CW; Heininger U; Chitkara AJ; Plotkin S Vaccine; 2018 Nov; 36(48):7270-7275. PubMed ID: 30337176 [TBL] [Abstract][Full Text] [Related]
12. Adverse events following primary and secondary immunisation with whole-cell pertussis: a systematic review protocol. Patterson J; Kagina BM; Gold M; Hussey GD; Muloiwa R BMJ Open; 2017 Jan; 7(1):e012945. PubMed ID: 28122832 [TBL] [Abstract][Full Text] [Related]
13. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. Greco D; Salmaso S; Mastrantonio P; Giuliano M; Tozzi AE; Anemona A; Ciofi degli Atti ML; Giammanco A; Panei P; Blackwelder WC; Klein DL; Wassilak SG N Engl J Med; 1996 Feb; 334(6):341-8. PubMed ID: 8538704 [TBL] [Abstract][Full Text] [Related]
14. Pertussis vaccination and whooping cough: and now what? Guiso N Expert Rev Vaccines; 2014 Oct; 13(10):1163-5. PubMed ID: 25020131 [TBL] [Abstract][Full Text] [Related]
15. Infant Whole-Cell Versus Acellular Pertussis Vaccination in 1997 to 1999 and Risk of Childhood Hospitalization for Food-Induced Anaphylaxis: Linked Administrative Databases Cohort Study. Pérez Chacón G; Fathima P; Jones M; Estcourt MJ; Gidding HF; Moore HC; Richmond PC; Snelling T J Allergy Clin Immunol Pract; 2024 Mar; 12(3):670-680. PubMed ID: 38182097 [TBL] [Abstract][Full Text] [Related]
16. Experience with monocomponent acellular pertussis combination vaccines for infants, children, adolescents and adults--a review of safety, immunogenicity, efficacy and effectiveness studies and 15 years of field experience. Thierry-Carstensen B; Dalby T; Stevner MA; Robbins JB; Schneerson R; Trollfors B Vaccine; 2013 Oct; 31(45):5178-91. PubMed ID: 23994021 [TBL] [Abstract][Full Text] [Related]
17. National Outbreak of Pertussis in England, 2011-2012: A Case-control Study Comparing 3-Component and 5-Component Acellular Vaccines With Whole-cell Pertussis Vaccines. Carvalho CFA; Andrews N; Dabrera G; Ribeiro S; Stowe J; Ramsay M; Amirthalingam G Clin Infect Dis; 2020 Jan; 70(2):200-207. PubMed ID: 31059566 [TBL] [Abstract][Full Text] [Related]
18. Bordetella Pertussis virulence factors in the continuing evolution of whooping cough vaccines for improved performance. Dorji D; Mooi F; Yantorno O; Deora R; Graham RM; Mukkur TK Med Microbiol Immunol; 2018 Feb; 207(1):3-26. PubMed ID: 29164393 [TBL] [Abstract][Full Text] [Related]
19. Investigating the pertussis resurgence in England and Wales, and options for future control. Choi YH; Campbell H; Amirthalingam G; van Hoek AJ; Miller E BMC Med; 2016 Sep; 14(1):121. PubMed ID: 27580649 [TBL] [Abstract][Full Text] [Related]
20. Pertussis vaccines: The first hundred years. Guiso N; Meade BD; Wirsing von König CH Vaccine; 2020 Jan; 38(5):1271-1276. PubMed ID: 31780181 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]